NCT03743259View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 29, 2018

Primary Completion Date

January 11, 2019

Study Completion Date

April 22, 2019

Conditions

Breast Diseases

Interventions

DRUG

LuminoMark inj. 0.1mL

Injection LuminoMark inj. (Conc. for fluorescence) 0.1mL once in this study.

DRUG

LuminoMark inj. 0.2mL

Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.

DRUG

Charcotrace Inj.

Injection Charcotrace Inj. about 0.3\~1mL once in this study.

Trial Locations (1)

06351

Samsung Medical Center, Seoul

All Listed Sponsors

lead

Hanlim Pharm. Co., Ltd.

INDUSTRY

NCT03743259 - To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions | Biotech Hunter | Biotech Hunter